Showing results (381-390 of 467) with videos related to

Sort By:
Pageof 47
International Journal of Obesity (2005)|July 8, 2009
Identification of waist circumference cutoffs for abdominal obesity in the Chinese population: a 7.8-year follow-up study in the Shanghai urban areaY Ye, Y Bao, X Hou, et al.
International Journal of Obesity (2005)|November 30, 2011
Contribution of visceral fat accumulation to carotid intima-media thickness in a Chinese populationY Wang, X Ma, M Zhou, et al.
Genetics and Molecular Research : GMR|February 25, 2016
Molecular cloning and expression analysis of MAT1 gene in black tiger shrimp (Penaeus monodon)Y Wang, M J Fu, C Zhao, et al.
Hua Xi Yi Ke Da Xue Xue Bao = Journal of West China University of Medical Sciences = Huaxi Yike Daxue Xuebao|September 1, 1989
[A study of acute toxicity of mitoxantrone]Z X Zeng, D Y Bao, Y Xiao, et al.
British Journal of Cancer|July 18, 2014
COUP-TFII regulates metastasis of colorectal adenocarcinoma cells by modulating Snail1Y Bao, D Gu, W Feng, et al.
Biochemical and Biophysical Research Communications|November 30, 1994
Nanosecond absorption study of kinetics associated with carbon monoxide rebinding to hemoglobin S and hemoglobin C following ligand photolysisD B Shapiro, S J Paquette, R M Esquerra, et al.
Medecine Et Maladies Infectieuses|January 2, 2007
[Principles of an outbreak investigation in public health practice]J-C Desenclos, V Vaillant, E Delarocque Astagneau, et al.
European Review for Medical and Pharmacological Sciences|April 22, 2016
N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activationX Wang, R Jiang, E-H Cui, et al.
The American Journal of Physiology|September 14, 1999
Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinitiesM L Pucci, Y Bao, B Chan, et al.
The British Journal of Dermatology|August 18, 2012
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trialB E Strober, J M Sobell, K C Duffin, et al.
Pageof 47